About MAbsolve
Our founders were pioneers of monoclonal antibody therapy, bringing to the clinic the first humanised antibody, the first made in CHO cells, the first bispecific and the first aglycosylated antibody. Now we have developed a new Fc variant which is more comprehensively silenced than previous antibodies. It is able to reduce unwanted inflammatory responses from the next generation of antibody-based drugs. We are building partnerships with Universities, Biotech and Pharma companies to make this new technology widely available.
|
|
|
1-10 employees
View all MAbsolve employees
|
|
Biotechnology Research
|
|
Oxford, Oxfordshire, GB
|
|
2019
|
|
Biotechnology, Licensing, Monoclonal Antibodies, Antibody Engineering, Immunogenicity, Complement, Cytokine Release, Fc Fusion Proteins, Fc Receptors
|
Search MAbsolve Staff Directory
Find accurate personal emails, work emails and phone numbers for employees
Supercharge your
Prospecting &
Outreach with
ContactOut
Supercharge your Prospecting &
Outreach with ContactOut
Search Portal
Find countless prospects outside of LinkedIn fast
Accelerate prospecting with instant access to 350M professionals from 40M companies with the right contact details.
